Month: September 2015

We are here live at the Sixth BHD Symposium and First Upstate Kidney Cancer Symposium, at the Upstate Medical University in Syracuse, New York. Upstate Medical University has an esteemed record in medical research and continues to focus on major healthcare challenges. The city of Syracuse also offers a beautiful and friendly backdrop to the Symposium. The … Read more

Partial nephrectomies are technically challenging surgeries but preserve healthy renal tissue and therefore function. To minimise bleeding the major blood vessels are usually clamped and tumour extraction completed under ischemic conditions – the renal tissue is deprived of oxygen and nutrients due to restricted blood flow. Although ischemic conditions for less than 25 minutes have … Read more

On September 24-26th the Sixth BHD and First Upstate Kidney Cancer Symposium will be taking place in Syracuse, New York. Hosted by Dr Medhi Mollapour and Professor Gennady Bratslavsky of the Upstate Medical University, it will focus on scientific and clinical developments in BHD and renal cell cancer. The Symposium will create networking opportunities for … Read more

mTOR is dysregulated in a range of tumour types and can be targeted with mTOR inhibitor treatments such as everolimus and sirolimus. Tuberous sclerosis complex (TSC) and sporadic lymphangioleiomyamatosis (LAM) result from mutations in TSC1 or TSC2 that disrupt mTOR signalling (Carsillo et al., 2000, Glasgow et al., 2010). The associated aberrant cell growth, survival and … Read more